J.C.-H. Yang

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Geoffrey R. Oxnard, J.C.-H. Yang, Helena A. Yu et al. · Annals of Oncology · 2020 · 425 citations

Medicine, Pharmacology, Pathology +7

Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)

Luis Paz‐Ares, E.H. Tan, L. Zhang et al. · Annals of Oncology · 2016 · 13 citations · Full text

Non-small-cell Lung Cancer, Overall Survival, Medicine +8

Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7

Lecia V. Sequist, Yi‐Long Wu, Martin Schüler et al. · Annals of Oncology · 2017 · 13 citations

Advanced Lung Disease, Medicine, Pathology +6

Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G

Corey J. Langer, S.M. Gaddgeel, Hossein Borghaei et al. · Annals of Oncology · 2016 · 10 citations · Full text

Advanced Nsclc, First-line Therapy, Oncology +8